Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.

Yonsei medical journal - 1 Jan 2017

Chang Hyun, Sung Ji Hea, Moon Sung Ung, Kim Han Soo, Kim Jin Won, Lee Jong Seok

Abstract excerpt

PURPOSE: Rearrangement of the proto-oncogene rearranged during transfection (RET) has been newly identified potential driver mutation in lung adenocarcinoma. Clinically available tyrosine kinase inhibitors (TKIs) target RET kinase activity, which suggests that patients with RET fusion genes may be treatable with a kinase inhibitor. Nevertheless, the mechanisms of resistance to these agents remain largely unknown....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cetuximab
Share to Hepatocyte Growth Factor
Share to Niacinamide

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phenylurea Compounds

Share to Piperidines

Share to Pyrroles

Share to Sorafenib

Share to Sunitinib

Source

Open in PubMed Open full text

Identifiers

PMID: 27873490
DOI: 10.3349/ymj.2017.58.1.9
PMCID: PMC5122657

Genes

RET
EGF
CCDC6
EGFR
HGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.PMID 27873490Read ↗

Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Semantic proximity Read ↗

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.Semantic proximity Read ↗

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.Semantic proximity Read ↗

<i><scp>RET</scp></i> fusion gene: Translation to personalized lung cancer therapySemantic proximity Read ↗

Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.Semantic proximity Read ↗

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.Semantic proximity Read ↗

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.Semantic proximity Read ↗

The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read ↗

Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.Semantic proximity Read ↗

Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.Semantic proximity Read ↗

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.